Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Morphine

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed2
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT01878006Phase 2CompletedPrimary

Genetic Effects on Dopamine Response to an Opiate

NCT01517061WithdrawnPrimary

Genetics and Phantom Limb Pain

NCT02225184Completed

Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans

Showing all 3 trials

Research Network

Common Treatments

  • Morphine1

Active Sponsors

  • National Institute on Drug Abuse (NIDA)2
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)1
  • National Institute of Nursing Research (NINR)1

Top Investigators

Related Conditions

  • Pain2
  • Addiction1
  • Drug Abusedependence1
  • Genetic Underpinning Of Substance Abuse1
  • Opiodrelated Disorders1

Activity Timeline